news aktuell GmbHnews aktuell GmbH

Grünenthal Group: Grünenthal’s Glucocorticoid Receptor Modulator enters clinical development

Share

(Aachen, Germany): Grünenthal announced today that the first volunteers have been enrolled in a Phase I trial of its Glucocorticoid Receptor Modulator (GRM). The oral investigational medicine aims to provide a therapy option with broad anti-inflammatory efficacy and a more favourable benefit-risk profile compared to current glucocorticoid-based therapies like prednisolone.

The Phase I trial includes 80 healthy volunteers and is designed as a head to head comparison between the GRM and prednisolone, the most frequently used glucocorticoid.[1] Observing several biomarkers, the trial will assess the influence of the investigational medicine on bone metabolism and glucose levels. Reduced bone formation leading to osteoporosis as well as increased blood glucose levels leading to an increased risk of diabetes are among the most common side-effects of glucocorticoids, which are a strong limitation for their long-term use at highly effective doses.[2],[3],[4] The results of the study are expected to be available in the first quarter of 2022.

“Millions of patients rely on glucocorticoid-based therapies to manage their condition and are therefore at risk to experience severe side effects”, says Jan Adams, M.D., Chief Scientific Officer, Grünenthal. “We strive to increase the quality of life for these patients during long-term treatments by providing a therapy option that delivers a broad anti-inflammatory efficacy with significantly fewer side effects.”

The investigational medicine is a Grünenthal proprietary development and is currently the most advanced compound of the company’s Glucocorticoid Receptor Modulator programme. Preclinically, the compound has shown anti-inflammatory properties comparable to prednisolone with a lower risk of glucocorticoid receptor mediated side effects.

This Phase I trial is Grünenthal’s latest milestone in progressing its research pipeline. Recently, the company announced another Phase I trial with its Nociceptin/Orphanin Peptid Receptor (NOP)-agonist for the treatment of chronic neuropathic pain. In addition, Grünenthal announced several Phase III studies investigating the efficacy, safety and tolerability of Qutenza® (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) and the efficacy, safety and tolerability of Resiniferatoxin in patients with pain associated with osteoarthritis of the knee. Both programmes are expected to start in 2021.

About Glucocorticoids

Glucocorticoids are a class of corticosteroids derived from the steroid hormone cortisol. Glucocorticoids are potent anti-inflammatory agents regardless of the cause of the inflammation and thus are used to suppress various allergic, inflammatory, and autoimmune disorders and to treat diseases caused by an overactive immune system. Long-term administration of Glucocorticoids can lead to a number of side effects, including osteoporosis and diabetes.


About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 29 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2020, Grünenthal employed around 4,500 people and achieved sales of € 1.3 bn.

More information: www.grunenthal.com

Follow us on:

LinkedIn: Grunenthal Group

Instagram: grunenthal




[1]Robert A. Overman, Jun-Yen Yeh, and Chad L. Deal; Prevalence of Oral Glucocorticoid Usage in the United States: A General Population Perspective; Arthritis Care & Research, Vol. 65, No. 2; February 2013; pp 294 –29. DOI 10.1002/acr.21796

[2]Liu X, Zhu X, Miao Q, Ye H, Zhang Z, Li Y; Hyperglycemia Induced by Glucocorticoids in Nondiabetic Patients: A Meta-Analysis; Ann Nutr Metab 2014; 65: 324-332. doi: 10.1159/000365892

[3] Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T; American College of Rheumatology. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25. doi: 10.1002/acr.22783. Epub 2015 Nov 6. PMID: 26545825.

[4]Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, Tran TN; Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018; 11: 193-204 https://doi.org/10.2147/JAA.S176026

Contacts

Christopher Jansen, Communication Business Partner
Grünenthal
Phone: +49 241 569-1428
Christopher.Jansen@grunenthal.com

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Visable GmbH: Applegate and Visable: B2B platform providers forge strategic partnership to strengthen international trade of UK-based businesses22.9.2021 15:22:17 CEST | Press release

Paris / Hamburg / Barnstaple, 22 September 2021 – Visable, the parent company of Europe’s leading online B2B platforms EUROPAGES and wlw (formerly "Wer liefert was"), and Applegate, the premier B2B marketplace in the United Kingdom, have entered into an exclusive partnership. As the official reselling partner in the UK, Applegate is able to offer listings and additional online marketing services on EUROPAGES and wlw alongside its own AI-based sourcing platform. As a result, companies in the UK benefit from greater visibility on the web to promote their products and services to procurement professionals across Europe.

MAAG Music & Arts AG: World premiere: Viva Frida Kahlo – Immersive Experience21.9.2021 14:05:16 CEST | Press release

(Zurich, Switzerland): The first museum for immersive art in Switzerland is opening with a world premiere: Viva Frida Kahlo – Immersive Experience. The preparations for this immersive enactment of the life and work of Frida Kahlo have been two years in the making. The exhibition will be unveiled on 22 September at the new Lichthalle MAAG in Zurich. It will be the first time that the life and work of the iconic Mexican artist will be presented in an immersive format outside of Mexico. Kahlo’s expressive paintings, with their accessible symbolism and colourful, exotic plants and animals, as well as her powerful self-portraits, are the perfect templates for an immersive presentation with video projections and light and sound effects. Visitors will experience Frida Kahlo’s life and work on a completely new level via panoramic projection. “Viva Frida Kahlo – Immersive Experience” offers an insight into the tragic life of the Mexican artist and her creations. Her pictures come to life in the

Justice Initiative: Barnemishandling i Europa: Offergrupper fra 17 land lanserer initiativ for å ta et oppgjør med barnemishandling i Europa20.9.2021 10:32:12 CEST | Pressemelding

På et internasjonalt møte i Sveits lanserte ofres grupper fra hele Europa "Justice Initiative". Med dette politiske initiativet skal overgrep, utnyttelse og andre krenkelser mot barn, spesielt i statlige og kirkelige institusjoner, behandles omfattende for første gang i alle europeiske land. Et forslag om å bringe behandlingen av overgrepssaker opp på et paneuropeisk nivå vil bli lagt frem for Europarådet i Strasbourg i september.

CONNECTED FUTURE20.9.2021 10:28:34 CEST | Pressemelding

The Media Art Festival Seasons of Media Arts is back again in the city! 17 September to 17 October, 2021 The urban Festival of Media Art Seasons of Media Arts is presenting a new edition for the Karlsruhe Summer of Culture 2021. Video, sound, and light installations, projections on facades and on streets, art interventions, and interactive projects with a special focus on local media artists will be on view from 17 September to 17 October 2021 in Karlsruhe’s public spaces.

FREE NOW: Europe’s leading mobility platform FREE NOW increases BEV tours by 71% in 202116.9.2021 11:02:22 CEST | Press release

After introducing its Move To Net-Zero carbon emissions initiative earlier this year, FREE NOW announces its achievements in 2021 on the occasion of the European Mobility Week, which starts today Since January 2021, FREE NOW trips using Battery Electric Vehicles (BEVs) have grown by 71% and the platform has added 20% new BEV active drivers In addition, FREE NOW has integrated almost 130,000 new eScooters, eBikes and electric shared cars in the app, widening its green mobility offer and becoming the mobility platform with the biggest vehicle choice in Europe FREE NOW has offset 173,000 tons of CO2 emissions, covering all the emissions produced by the company and its services from the beginning of 2020 onwards The leading mobility platform will participate in the EU Mobility Week with a number of different activities to raise awareness of sustainable urban mobility (Hamburg, Germany): – FREE NOW, Europe’s leading multi-service mobility platform, today publishes its latest electric vehicl

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom